India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
Dhar has been selected for the Safe Cities Project 2026 and it marks the major…
The Athletics Integrity Unit (AIU) have upgraded the India to the Category A. This category…
Education has a long and rich history. Some universities in the world were built hundreds…
The Archaeological Survey of India (ASI) has started the important conservation operation at the Konark…
River islands are special landforms that form inside rivers when soil, sand, and small rocks…
UK Parliament has approved the Tobacco and Vapes Bill which will permanently ban the individuals…